Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Sunshine Biopharma (SBFM) Accumulated Depreciation & Amortization (2022 - 2026)

Sunshine Biopharma filings provide 5 years of Accumulated Depreciation & Amortization readings, the most recent being $512879.0 for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 52.4% to $512879.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $512879.0, a 52.4% increase, with the full-year FY2025 number at $512879.0, up 52.4% from a year prior.
  • Accumulated Depreciation & Amortization hit $512879.0 in Q4 2025 for Sunshine Biopharma, up from $462469.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $512879.0 in Q4 2025 to a low of $83806.0 in Q4 2022.
  • Median Accumulated Depreciation & Amortization over the past 4 years was $369180.0 (2025), compared with a mean of $338212.7.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 126.71% in 2023 and later soared 52.4% in 2025.
  • Sunshine Biopharma's Accumulated Depreciation & Amortization stood at $83806.0 in 2022, then skyrocketed by 126.71% to $189996.0 in 2023, then soared by 77.13% to $336533.0 in 2024, then soared by 52.4% to $512879.0 in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $512879.0 (Q4 2025), $462469.0 (Q3 2025), and $412626.0 (Q2 2025) per Business Quant data.